← Back to Clinical Trials
Recruiting NCT05988879

Functional Cure of Hepatitis B in HIV/HBV Co-infected Patients

Trial Parameters

Condition AIDS
Sponsor Guangzhou 8th People's Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 60
Sex ALL
Min Age 18 Years
Max Age 65 Years
Start Date 2023-08-02
Completion 2026-08-02
All Conditions
Interventions
Peginterferon alfa-2b Injection

Brief Summary

Evaluate the potential of ART combined with interferon therapy to achieve functional cure of hepatitis B in HIV/HBV co-infected patients

Eligibility Criteria

Inclusion Criteria: 1. Age 18-65 years old, gender unrestricted. 2. Meeting the People's Republic of China Health Industry Standard (WS293-2008) - "AIDS and HIV Infection Diagnostic Criteria", confirmed as HIV-1 infected. 3. HBsAg positive for more than 6 months. 4. At least 1 year of ART treatment prior to screening, and currently undergoing ART treatment with HBsAg \<1000IU/mL, HBeAg negative, HBV DNA \<100IU/ml, CD4+T lymphocyte count \>200 cells/μL and HIV-RNA\<20 copies/ml. Exclusion Criteria: 1. Pregnant, nursing, planning pregnancy, or with severe mental disorders or uncontrolled epilepsy. 2. Co-infected with Hepatitis A, C, D, or E viruses. 3. With other chronic liver diseases like autoimmune hepatitis, drug-induced hepatitis, alcoholic hepatitis, genetic metabolic liver diseases, or moderate to severe fatty liver. 4. With autoimmune diseases like rheumatoid arthritis, psoriasis, or lupus. 5. Post organ transplant, planning organ transplant, diagnosed or suspected of liver canc

Related Trials